ABAmmad Anwar Baig

Ammad Anwar Baig

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ammad Anwar Baig has a total of 188 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Validity of Woven EndoBridge sizing based on the device-to-aneurysm volume ratio

    by Elliot Pressman, Joshua H Weinberg, Ammad A Baig, Gersham J Rainone, Samantha Schimmel, Joshua Vignolles-Jeong, Teagen Smith, Patrick Youssef, Jason M Davies, Adnan H Siddiqui, et al.

    Background: The Woven EndoBridge (WEB) is a treatment modality available for the treatment of intracranial aneurysms, specifically beneficial in wide-necked bifurcation aneurysms. Conventional sizing methods rely on the manipulation of aneurysm width and height measurements. This results in frequent need for re-sizing after initial WEB insertion attempts. Previous studies have suggested that volume-based sizing may decrease this rate. Methods: We conducted a multicenter retrospective cohort study in three complex vascular centers in the United States from 1 January 2020 to 30 June 2023. All patients who underwent attempted aneurysmal WEB embolization were included. Using three-dimensional angiogram reconstructions, we measured the aneurysm volume. We calculated the WEB volume and measured the WEB-aneurysm volume (WAVe) ratio. The primary outcome was whether a WEB required re-sizing. Results: A total of 133 cases were identified, 114 correctly sized and 19 incorrectly sized. Twelve patients (9.0%) required additional stent placement during WEB insertion. One patient (0.8%) had WEB abandonment. There were no differences in demographic or baseline characteristics between the size/re-sizing cohorts aside from aneurysm location (“other” and basilar locations increased the rate of re-sizing). The median WAVe ratio in our appropriately sized cohort was 0.997 (interquartile range (IQR) 0.826, 1.30) versus 1.14 in our re-sizing cohort (IQR 0.734, 1.51; p = 0.728). Using logistic regression, we identified a WAVe ratio ranging from 0.76 to 1.24 yielding > 80% probability of a successful sizing with 95% confidence. Conclusions: Incorporating volume-based measurements in aneurysm embolization with WEBs may improve rates of re-sizing but has an unclear effect on aneurysm occlusion. A WAVe ratio of 0.76–1.24 provides the greatest probability of appropriate initial WEB sizing.


  • Impact of duration of dual anti-platelet therapy on risk of complications after stent-assisted coiling of unruptured aneurysms

    by Andrew J Ringer, Ricardo A Hanel, Ammad A Baig, Adnan H Siddiqui, Demetrius Klee Lopes, Guilherme Barros, David I Bass, Michael R Levitt, Christopher C Young, Ryan M Naylor, et al.

    Background The optimal duration for dual antiplatelet therapy (DAPT) after stent-assisted coiling (SAC) of intracranial aneurysms is unclear. Longer-term therapy may reduce thrombotic complications but increase the risk of bleeding complications. Methods A retrospective review of prospectively maintained data at 12 institutions was conducted on patients with unruptured intracranial aneurysms who underwent SAC between January 1, 2016 and December 31, 2020, and were followed ≥6 months postprocedure. The type and duration of DAPT, stent(s) used, outcome, length of follow-up, complication rates, and incidence of significant in-stent stenosis (ISS) were collected. Results Of 556 patients reviewed, 450 met all inclusion criteria. Nine patients treated with DAPT 42 days after SAC did not reduce the risk of thrombotic complications or in-stent stenosis, although the risk of additional hemorrhagic complications remained low. It may be reasonable to discontinue DAPT after 42 days following non-flow diverting SAC of unruptured intracranial aneurysms.


  • Efficacy of intra-arterial carboplatin and bevacizumab in the C6 rat glioma model of glioblastoma multiforme

    by Jaims Lim, Briana A Santo, Ammad A Baig, Shiau-Sing K Ciecierska, Brianna Donnelly, Sarah Balghonaim, Bennett R Levy, Vinay Jaikumar, Elad I Levy, Vincent M Tutino, et al.

    Background Utilizing an endovascular rat glioma model, this study aimed to analyze the efficacy of intra-arterial (IA) carboplatin and bevacizumab delivery with blood-brain barrier breakdown (BBBB) for glioblastoma treatment. Methods C6-glioma cells were stereotactically injected into the left frontal lobe of Wistar rats. Tumor growth was confirmed on day 8 via MRI. On day 9, a microcatheter was navigated under fluoroscopy from the left femoral artery to the left internal carotid artery. A volume of 2.25 mL of 25% mannitol was administered, followed by either 10 mg/kg of bevacizumab or 2.4 mg/kg of carboplatin. Serial MRI was obtained post-treatment to assess tumor response via analysis of tumor size and radiomics. Histology was analyzed after termination. Results Control tumor rats and IA mannitol treated tumor rats had fatal tumor growths, with survival until 19.75±2.21 and 36.3±15.1 days, respectively. Carboplatin and bevacizumab treated rats lived >40 days, after which they were euthanized. From serial MRI and histology, IA carboplatin treated rats exhibited tumor regression and resolution by day 35. In IA bevacizumab treated rats, there was tumor regression near the basal ganglia of the brain, closer to the IA chemotherapy injection site, which had reorganized growth patterns. From MRI, 29 unique radiomic features were significantly different between control and treated tumors (notably for total energy and skewness), and treatment responders had a distinct, early manifesting radiomic profile. Conclusion IA carboplatin and bevacizumab treatment resulted in varying degrees of tumor suppression, validating the first endovascular C6 glioma model as a reliable method to assess new IA therapies.


  • Femoral versus radial access for middle meningeal artery embolization for chronic subdural hematomas: multicenter propensity score matched study

    by Mohamed M Salem, Georgios S Sioutas, Avi Gajjar, Jane Khalife, Okkes Kuybu, Kate T Carroll, Alex Nguyen Hoang, Ammad A Baig, Mira Salih, Cordell Baker, et al.

    Background With transradial access (TRA) being more progressively used in neuroendovascular procedures, we compared TRA with transfemoral access (TFA) in middle meningeal artery embolization (MMAE) for chronic subdural hematoma (cSDH). Methods Consecutive patients undergoing MMAE for cSDH at 14 North American centers (2018–23) were included. TRA and TFA groups were compared using propensity score matching (PSM) controlling for: age, sex, concurrent surgery, previous surgery, hematoma thickness and side, midline shift, and pretreatment antithrombotics. The primary outcome was access site and overall complications, and procedure duration; secondary endpoints were surgical rescue, radiographic improvement, and technical success and length of stay. Results 872 patients (median age 73 years, 72.9% men) underwent 1070 MMAE procedures (54% TFA vs 46% TRA). Access site hematoma occurred in three TFA cases (0.5%; none required operative intervention) versus 0% in TRA (P=0.23), and radial-to-femoral conversion occurred in 1% of TRA cases. TRA was more used in right sided cSDH (58.4% vs 44.8%; PConclusions In this study, TRA offered comparable outcomes to TFA in MMAE for cSDH in terms of access related and overall complications, technical feasibility, and functional outcomes. Procedural duration was slightly longer in the TRA group, and radiographic success was higher in the TFA group, with no differences in surgical rescue rates.


  • The Influence of Coagulopathy on Radiographic and Clinical Outcomes in Patients Undergoing Middle Meningeal Artery Embolization as Standalone Treatment for Non-acute Subdural Hematomas

    by Walid K. Salah, Matthew C. Findlay, Cordell M. Baker, Jonathan P. Scoville, Michael T. Bounajem, Christopher S. Ogilvy, Justin M. Moore, Howard A. Riina, Elad I. Levy, Adnan H. Siddiqui, et al.

    Middle meningeal artery embolization (MMAE) is emerging as a safe and effective standalone intervention for non-acute subdural hematomas (NASHs); however, the risk of hematoma recurrence after MMAE in coagulopathic patients is unclear. To characterize the impact of coagulopathy on treatment outcomes, we analyzed a multi-institutional database of patients who underwent standalone MMAE as treatment for NASH. We classified 537 patients who underwent MMAE as a standalone intervention between 2019 and 2023 by coagulopathy status. Coagulopathy was defined as use of anticoagulation/antiplatelet agents or pre-operative thrombocytopenia (platelets p < 0.05). On matched multivariable analysis, patients with coagulopathy had an increased odds ratio (OR) of requiring surgical rescue (OR 3.95; 95% confidence interval [CI] 1.68–9.30; p < 0.01). Antiplatelet agent use (ticagrelor, prasugrel, or clopidogrel) was also predictive of surgical rescue (OR 4.38; 95% CI 1.51–12.72; p = 0.01), and patients with thrombocytopenia had significantly increased odds of in-hospital mortality (OR 5.16; 95% CI 2.38–11.20; p < 0.01). There were no differences in follow-up radiographic and other clinical outcomes in patients with and those without coagulopathy. Patients with coagulopathy undergoing standalone MMAE for treatment of NASH may have greater risk of requiring surgical rescue (particularly in patients using antiplatelet agents), and in-hospital mortality (in thrombocytopenic patients).


  • Cerebral emboli detection and autonomous neuromonitoring using robotic transcranial Doppler with artificial intelligence for transcatheter aortic valve replacement with and without embolic protection devices: a pilot study

    by Ammad A Baig, Christopher Manion, Wasiq I Khawar, Brianna M Donnelly, Kunal Raygor, Ryan Turner, David R Holmes, Vijay S Iyer, L Nelson Hopkins, Jason M Davies, et al.

    Background: Periprocedural ischemic stroke remains a serious complication in patients undergoing transcatheter aortic valve replacement (TAVR). We used a novel robotic transcranial Doppler (TCD) system equipped with artificial intelligence (AI) for real-time continuous intraoperative neuromonitoring during TAVR to establish the safety and potential validity of this tool in detecting cerebral emboli, report the quantity and distribution of high intensity transient signals (HITS) with and without cerebral protection, and correlate HITS occurrence with various procedural steps.Methods: Consecutive patients undergoing TAVR procedures during which the robotic system was used between October 2021 and May 2022 were prospectively enrolled in this pilot study. The robotic TCD system included autonomous adjustment of the TCD probes and AI-assisted post-processing of HITS and other cerebral flow parameters. Basic demographics and procedural details were recorded. Continuous variables were analyzed by a two-sample Mann–Whitney t-test and categorical variables by a χ2or Fisher test.Results: Thirty-one patients were prospectively enrolled (mean age 79.9±7.6 years; 16 men (51.6%)). Mean aortic valve stenotic area was 0.7 cm2and mean aortic–ventricular gradient was 43 mmHg (IQR 31.5–50 mmHg). Cerebral protection was used in 16 cases (51.6%). Significantly fewer emboli were observed in the protection group than in the non-protection group (mean 470.38 vs 693.33; p=0.01). Emboli counts during valve positioning and implantation were significantly different in the protection and non-protection groups (mean 249.92 and 387.5, respectively; p=0.01). One (4%) transient ischemic attack occurred post-procedurally in the non-protection group.Conclusion: We describe a novel real-time intraoperative neuromonitoring tool used in patients undergoing TAVR. Significantly fewer HITS were detected with protection. Valve positioning–implantation was the most significant stage for intraprocedural HITS.


  • Standalone middle meningeal artery embolization versus middle meningeal artery embolization with concurrent surgical evacuation for chronic subdural hematomas: a multicenter propensity score matched analysis of clinical and radiographic outcomes

    by Huanwen Chen, Mohamed M Salem, Marco Colasurdo, Georgios S Sioutas, Jane Khalife, Okkes Kuybu, Kate T Carroll, Alex Nguyen Hoang, Ammad A Baig, Mira Salih, et al.

    Background Middle meningeal artery embolization (MMAE) has emerged as a promising therapy for chronic subdural hematomas (cSDHs). The efficacy of standalone MMAE compared with MMAE with concurrent surgery is largely unknown. Methods cSDH patients who underwent successful MMAE from 14 high volume centers with at least 30 days of follow-up were included. Clinical and radiographic variables were recorded and used to perform propensity score matching (PSM) of patients treated with standalone MMAE or MMAE with concurrent surgery. Multivariable logistic regression models were used for additional covariate adjustments. The primary outcome was recurrence requiring surgical rescue, and the secondary outcome was radiographic failure defined as Results 722 MMAE procedures in 588 cSDH patients were identified. After PSM, 230 MMAE procedures remained (115 in each group). Median age was 73 years, 22.6% of patients were receiving anticoagulation medication, and 47.9% had no preoperative functional disability. Median midline shift was 4 mm and cSDH thickness was 16 mm, representing modestly sized cSDHs. Standalone MMAE and MMAE with surgery resulted in similar rates of surgical rescue (7.8% vs 13.0%, respectively, P=0.28; adjusted OR (aOR 0.73 (95% CI 0.20 to 2.40), P=0.60) and radiographic failure (15.5% vs 13.7%, respectively, P=0.84; aOR 1.08 (95% CI 0.37 to 2.19), P=0.88) with a median follow-up duration of 105 days. These results were similar across subgroup analyses and follow-up durations. Conclusions Standalone MMAE led to similar and durable clinical and radiographic outcomes as MMAE combined with surgery in select patients with moderately sized cSDHs and mild clinical disease.


  • Analysis of craniectomy bone flaps stored in a neurosurgical cryopreservation freezer: microorganism culture results and reimplantation rates

    by Brianna M. Donnelly, David E. Smolar, Ammad A. Baig, Mohamed A. R. Soliman, Andre Monteiro, Kevin J. Gibbons, Elad I. Levy, Kenneth V. Snyder

    Background Cryopreservation of bone flaps after decompressive craniectomies is a common practice. A frequent complication after bone flap reimplantation is postoperative infection, so culturing of frozen craniectomy bone flaps is a crucial practice that can prevent patient morbidity and mortality. Although many studies report on infection rates after cranioplasty, no study reports on the results of bone flaps stored in a cryopreservation freezer, reimplanted or otherwise. We sought to analyze the flaps in our medical center’s bone bank freezer, including microorganism culture results and reimplantation rates of cryopreserved bone flaps. Methods Patients who underwent craniectomy and had bone flaps cryopreserved between January 1, 2016, and July 1, 2022, were included in this retrospective study. Information about bone flap cultures and reimplantation or discard was obtained from a prospectively maintained cryopreservation database. Information including infection rates and mortality was acquired from a retrospective review of patient records. Culture results were obtained for all flaps immediately before cryopreservation and again at the time of reimplantation at the operator’s discretion. Results There were 148 bone flaps obtained from 145 patients (3 craniectomies were bilateral) stored in our center’s freezer. Positive culture results were seen in 79 (53.4%) flaps. The most common microorganism genus was Propionibacterium with 47 positive flaps, 46 (97.9%) of which were P. acnes. Staphylococcus was the second most common with 23 positive flaps, of which 8 (34.8%) tested positive for S. epidermidis. Of the 148 flaps, 25 (16.9%) were reimplanted, 116 (78.4%) were discarded, and 7 (4.7%) are still being stored in the freezer. Postcranioplasty infections were seen in 3 (12%) patients who had flap reimplantation. Conclusions Considering the substantial number of positive cultures and limited reimplantation rate, we have reservations about the logistical efficiency of cryopreservation for flap storage. Future multicenter studies analyzing reimplantation predictors could help to reduce unnecessary freezing and culturing.


  • Open Access

    Mechanical thrombectomy in medium vessel occlusions using the novel aspiration Q catheters: an international multicenter experience

    by Andre Monteiro, Hegoda Levansri Dilrukshan Makalanda, James Wareham, Jesse Jones, Ammad A Baig, Permesh Singh Dhillon, Pervinder Bhogal, Maxim Mokin, Waleed Brinjikji, Adnan H Siddiqui

    Background Medium vessel occlusions (MeVOs) comprise a large proportion of all stroke events. We performed a multicenter study of MIVI Q catheters, a novel design that optimizes suction forces without an increase in lumen diameter, for the treatment of MeVOs, aiming to evaluate its efficacy and safety. Methods Databases of two US and two UK centers were retrospectively reviewed for MeVO patients (M2-M3, anterior cerebral artery (ACA), or posterior cerebral artery (PCA)) treated with Q catheters. Outcomes were assessed as successful recanalization (modified Thrombolysis in Cerebral Infarction (mTICI) score ≥2b), first pass effect (FPE), and modified FPE (mFPE) as single pass achieving mTICI ≥2c and mTICI≥2b, respectively, and 90 day modified Rankin Scale (mRS) score. Results 69 patients were included (median age 71 years, IQR 56–82.5; 52.2% men). Median National Institutes of Health Stroke Scale (NIHSS) score at admission was 14, and Alberta Stroke Program Early CT Score (ASPECTS) was 9. Primary (without large vessel occlusion (LVO)) and secondary (with LVO) MeVOs represented 47.8% and 52.2% of cases, respectively. Q catheters used were Q3 (47.8%), Q4 (33.3%), Q5 (10.1%), and Q6 (8.7%). mTICI≥2b was achieved in 92.8% of patients, with FPE in 47.8%, and mFPE in 68.1%. Two (2.9%) intraprocedural complications (symptomatic intracranial hemorrhage) occurred. 50% (27/54) achieved an mRS score of ≤2 at the 90 day follow-up. The median NIHSS at admission was significantly higher in secondary than in primary MeVOs (19.5 vs 12, P=0.009). The rate of mRS ≤2 at 90 days was significantly higher in primary than in secondary MeVOs (77.3% vs 31.3%, P=0.002). Conclusions Treatment of MeVO patients with Q catheters resulted in optimal angiographic and clinical outcomes. Although angiographic results were similar between primary and secondary MeVOs, the former had less severe presenting NIHSS and better outcomes at 90 days than the latter.


  • Standalone versus Anterior Cervical Plating for One-To-Two Level Anterior Cervical Discectomy and Fusion: A Propensity Score-Matched Comparative Study

    by Ammad A. Baig, Alexander O. Aguirre, Mohamed A.R. Soliman, Cathleen C. Kuo, Jaims Lim, Asham Khan, Ivette Chen, Kenneth V. Snyder, Elad I. Levy, Adnan H. Siddiqui, et al.